7 participants
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-10-17
- Start Date:
- 2021-09-13
- Completion:
- 2022-06-01
Conditions
- COVID-19
Interventions
- DRUG